Ludwig Merker

1.8k total citations · 1 hit paper
30 papers, 1.4k citations indexed

About

Ludwig Merker is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Ludwig Merker has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Ludwig Merker's work include Diabetes Treatment and Management (23 papers), Diabetes Management and Research (17 papers) and Pancreatic function and diabetes (8 papers). Ludwig Merker is often cited by papers focused on Diabetes Treatment and Management (23 papers), Diabetes Management and Research (17 papers) and Pancreatic function and diabetes (8 papers). Ludwig Merker collaborates with scholars based in Germany, United States and France. Ludwig Merker's co-authors include Uli C. Broedl, Hans J. Woerle, Thomas Meinicke, Marc Weimer, Hans‐Ulrich Häring, Elke Seewaldt-Becker, Afshin Salsali, Flavien Roux, Anita Vedel Christiansen and John B. Buse and has published in prestigious journals such as The Lancet, Diabetes Care and Diabetic Medicine.

In The Last Decade

Ludwig Merker

22 papers receiving 1.3k citations

Hit Papers

Empagliflozin as Add-On to Metformin in Patients With Typ... 2014 2026 2018 2022 2014 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    2014 315 citations Hans‐Ulrich Häring, Ludwig Merker et al. Diabetes Care profile →

Peers

Ludwig Merker
Aurora Merovci United States
Zin Zin Htike United Kingdom
Elke Seewaldt-Becker Germany
Katja Rohwedder Germany
Aliza Rozenberg Israel
Ilan Yanuv Israel
Lin Ping United States
Markus F. Scheerer Germany
Michaël J.B. van Baar Netherlands
Vanessa Ronconi Italy
Aurora Merovci United States
Ludwig Merker
Citations per year, relative to Ludwig Merker Ludwig Merker (= 1×) peers Aurora Merovci

Countries citing papers authored by Ludwig Merker

Since Specialization
Citations

This map shows the geographic impact of Ludwig Merker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ludwig Merker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ludwig Merker more than expected).

Fields of papers citing papers by Ludwig Merker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ludwig Merker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ludwig Merker. The network helps show where Ludwig Merker may publish in the future.

Co-authorship network of co-authors of Ludwig Merker

This figure shows the co-authorship network connecting the top 25 collaborators of Ludwig Merker. A scholar is included among the top collaborators of Ludwig Merker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ludwig Merker. Ludwig Merker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merker, Ludwig, Thomas Ebert, Martina Guthoff, & Berend Isermann. (2023). Nephropathy in Diabetes. Experimental and Clinical Endocrinology & Diabetes. 131(01/02). 61–65.
2.
Merker, Ludwig, Thomas Ebert, Erwin Schleicher, Martina Guthoff, & Berend Isermann. (2023). Nephropathie bei Diabetes. Diabetologie und Stoffwechsel. 18(S 02). S342–S347. 4 indexed citations
3.
Merker, Ludwig, Thomas Ebert, Martina Guthoff, & Berend Isermann. (2022). Nephropathie bei Diabetes. Diabetologie und Stoffwechsel. 17(S 02). S327–S331. 3 indexed citations
4.
Merker, Ludwig. (2021). Nierenschaden bei Diabetes frühzeitig erkennen!. MMW - Fortschritte der Medizin. 163(8). 48–51. 4 indexed citations
5.
Merker, Ludwig, Thomas Ebert, Martina Guthoff, et al.. (2019). Nephropathie bei Diabetes. Der Diabetologe. 15(6). 568–572. 1 indexed citations
6.
Heinemann, Lutz, Patricia Kaiser, Guido Freckmann, et al.. (2018). HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose?. Diabetologie und Stoffwechsel. 13(1). 46–53. 12 indexed citations
7.
Heinemann, Lutz, Patricia Kaiser, Guido Freckmann, et al.. (2018). Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany. Hormone and Metabolic Research. 50(10). 728–734. 14 indexed citations
8.
Roden, Michael, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology. 14(1). 154–154. 101 indexed citations
9.
Kovács, Christopher S., Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics. 37(8). 1773–1788.e1. 91 indexed citations
10.
Haering, Hans-Ulrich, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 110(1). 82–90. 67 indexed citations
11.
Merker, Ludwig, H.-U. Häring, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as add‐on to metformin in people with Type 2 diabetes. Diabetic Medicine. 32(12). 1555–1567. 68 indexed citations
12.
Häring, HU, et al.. (2015). Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. Diabetologie und Stoffwechsel. 10(S 01). 1 indexed citations
13.
Morales, Javier & Ludwig Merker. (2015). Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). Advances in Therapy. 32(5). 391–403. 6 indexed citations
14.
Häring, Hans‐Ulrich, Ludwig Merker, Elke Seewaldt-Becker, et al.. (2014). Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 37(6). 1650–1659. 315 indexed citations breakdown →
15.
Häring, Hans‐Ulrich, Ludwig Merker, Elke Seewaldt-Becker, et al.. (2013). Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes. Diabetes Care. 36(11). 3396–3404. 305 indexed citations
16.
17.
Merker, Ludwig. (2012). Tipps zum praktischen Einsatz. 6(1). 40–45.
18.
Merker, Ludwig. (2012). Anwendung inkretinbasierter Therapien bei Patienten mit Niereninsuffizienz. Diabetologie und Stoffwechsel. 7(4). 308–308.
19.
20.
Landgraf, R., et al.. (2008). Hypertonie beim Diabetes mellitus. Diabetologie und Stoffwechsel. 3(S 2). S141–S142. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aurora Merovci Breakdown of academic impact, for papers by Zin Zin Htike Breakdown of academic impact, for papers by Elke Seewaldt-Becker Breakdown of academic impact, for papers by Katja Rohwedder Breakdown of academic impact, for papers by Aliza Rozenberg Breakdown of academic impact, for papers by Ilan Yanuv Breakdown of academic impact, for papers by Lin Ping Breakdown of academic impact, for papers by Markus F. Scheerer Breakdown of academic impact, for papers by Michaël J.B. van Baar Breakdown of academic impact, for papers by Vanessa Ronconi
Rankless by CCL
2026